Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Prodrugs of anti-platelet agents

A technology of prodrugs and solvates, which is applied in the field of compounds and compositions for the treatment of atherosclerosis and thrombosis, and can solve unclear problems

Inactive Publication Date: 2015-02-25
CELLIXBIO PTE LTD
View PDF15 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is controversy regarding the choice of oral antiplatelet therapy in patients with vascular disease (ie, ischemic stroke, coronary artery disease [CAD], and peripheral artery disease [PAD])
Although aspirin has been approved for prevention of recurrent atherothrombotic events in a broad range of high-risk patients (approximately 25% relative risk reduction), it is less clear how well other antiplatelet agents, such as clopidogrel Or whether dipyridamole is more effective alone or added to aspirin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Prodrugs of anti-platelet agents
  • Prodrugs of anti-platelet agents
  • Prodrugs of anti-platelet agents

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0075] definition

[0076] As used herein, the following terms and phrases shall have the meanings set forth below. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.

[0077] The compounds of the present invention may exist in the form of pharmaceutically acceptable salts. The compounds of the invention may also exist in the form of pharmaceutically acceptable esters (ie, methyl and ethyl esters of acids of Formula I, Formula II, Formula Ia or Formula Ha to be used as prodrugs). The compounds of the invention may also be solvated, ie hydrated. Solvation may act or occur (hydration) during the manufacturing process, ie due to the hygroscopic nature of the initially anhydrous compound of Formula I, Formula II, Formula Ia or Formula IIa.

[0078] Compounds that have the same molecular formula but differ in the nature or in the sequence in which their atoms are joined or in ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
Login to View More

Abstract

Disclosed is the compounds of formula (I), formula (II), formula (la), formula (IIb) or its pharmaceutical acceptable salts, polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising and effective amount of formula (I), formula (II), formula (la), formula (lIb) and may be used to treatment or management of ischemia, stroke, cerebral thrombosis, arterial thrombosis, thrombotic cerebrovascular, cardiovasculard diseases and blood colts.

Description

[0001] priority [0002] This application claims the benefit of Indian Provisional Patent Application No. 1781 / CHE / 2012 filed on May 7, 2012 and International Application No. PCT / IB2012 / 053673 filed on July 19, 2012, the full disclosures of which applications The content is relied upon for all purposes and is incorporated by reference into this application. technical field [0003] The present disclosure relates generally to compounds and compositions useful in the treatment of atherothrombosis. More specifically, the invention relates to the treatment of a subject with a pharmaceutically acceptable dose of a compound, stereoisomer, enantiomer, crystal, ester, salt, hydrate, prodrug, or mixture thereof. Background technique [0004] Atherothrombosis is the formation of superimposed thrombus on pre-existing atherosclerosis. This common pathophysiological process results in morbid or fatal clinical ischemic events affecting the brain, coronary arteries, or peripheral arteria...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D495/04C07D211/72A61K31/4365A61K31/445A61P25/00A61P9/00A61P7/02
CPCC07D495/04C07D211/72C07D409/12A61P7/02A61P9/00A61P9/10A61P25/00
Inventor M·坎杜拉
Owner CELLIXBIO PTE LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com